2012
DOI: 10.1200/jco.2012.30.5_suppl.467
|View full text |Cite
|
Sign up to set email alerts
|

MARC-2: An open-label trial to characterize patients with metastatic renal cell carcinoma (mRCC) treated with everolimus after failure of the first VEGFR-TKI therapy.

Abstract: 467 Background: Clinical research in mRCC is leading to increased treatment options. Most patients (pts) are treated with sequenced systemic medications based on the clinical course of the disease. Characterization of pts most likely to benefit from a specific targeted agent has not yet been sufficiently addressed in this area. So far, no reliable biomarkers exist to predict therapy response or resistance in the individual patient. Further investigation is needed to understand drug effects in vivo. In the MAR… Show more

Help me understand this report

This publication either has no citations yet, or we are still processing them

Set email alert for when this publication receives citations?

See others like this or search for similar articles